NeuBase Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Sep 30, 2022	FY2021 12 months to Sep 30, 2021	FY2020 12 months to Sep 30, 2020	FY2019 12 months to Sep 30, 2019	FY2018 12 months to Sep 30, 2018
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Common stock issued for services
Stock-based compensation
Depreciation
Amortization of intangible assets
Gain on settlement of liabilities
Research and development expense, Vera acquisition
Research and development, Vera acquisition
Change in fair value of warrant liabilities
Depreciation and amortization
Non-cash amortization on convertible notes discount
Loss on marketable securities
Loss on disposal of fixed assets
Equity in losses on equity method investment
Non-cash amortization on convertible notes
Non-cash interest expense on convertible notes
Gain on sale of intellectual property
Loss on Impairment of goodwill and intangible assets
Non-cash expense from right-of-use assets
Amortization of right-of-use assets

Changes in operating assets and liabilities
Prepaid insurance, other prepaid expenses and current assets
Accounts payable and accrued expenses
Long-term prepaid insurance
Security deposit
Other long-term assets
Accounts payable
Accrued expenses and other current liabilities
Operating lease liability
Net cash used in operating activities

Proceeds from sale of property and equipment and intangible assets

Cash flows from investing activities
Purchase of laboratory and office equipment
Cash acquired in connection with Acquisition of Ohr
Payment of transaction costs for Acquisition of Ohr
Payment of transaction costs for licenses acquired- CMU
Cash paid for license acquired
Purchase of marketable securities
Sale of marketable securities
Cash paid for Vera acquisition
Net cash used in investing activities
Cash flows from financing activities
Principal payment of financed insurance
Principal payment of finance lease liability
Proceeds from warrants exercised for cash
Repayments of short-term notes payable
Proceeds from exercise of stock options
Proceeds from issuance of common stock in pre-acquisition financing, net of issuance costs
Proceeds from issuance of common stock in private placement financing, net of issuance costs
Proceeds from issuance of convertible notes
Payment for warrant redemption
Proceeds from issuance of common shares for services
Proceeds from prefunded warrant
Repurchase of common stock
Net cash (used in) provided by financing activities
NET CHANGE IN CASH
CASH AT BEGINNING OF PERIOD
CASH AT END OF PERIOD

Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Supplemental disclosure of cash flow information:
Cash paid for interest
Financing of insurance premiums through issuance of short term notes
Cash paid for income taxes
Non-cash investing and financing activities:
Issuance of common stock for research and development expense-licenses acquired- CMU
Issuance of common stock and options for acquisition of Ohr
Fair value of warrant liability issued for research and development expense- licenses acquired
Issuance of common stock for conversion of debt
Issuance of common stock for conversion of accrued interest
Issuance of common stock for the cashless exercise of warrant
Issuance of common stock, Vera acquisition
Purchases of laboratory and office equipment in accounts payable
Preferred shares in DepYmed received as consideration for sale of intellectual property
Insurance financed through note payable
Capital expenditures in accounts payable
Right-of-use asset obtained in exchange for operating lease liabilities
Deferred offering costs accrued

Comments